Braskem Q4: Challenging But Opportune Scenario For Patient Investors
Source: SeekingAlpha
2025-03-30 16:21:05 ET
Summary
- Braskem's net revenues fell 14% q/q and 2% y/y in 4Q24 due to reduced petrochemical spreads and lower demand.
- Despite high leverage, Braskem's $2.4 billion cash ensures debt coverage for the next 47 months, projecting operational cash recovery.
- Valuation comparison with peers suggests a 19% upside, reinforcing my buy recommendation despite challenging market conditions.
- Future margin improvements are expected through operational efficiency and capacity rationalization, with moderate gains projected for 2025.
Investment Thesis
I reiterate my recommendation to buy Braskem (NYSE: BAK ) shares after the release of its Q4 results. This article is a continuation of my inception thesis published on June 14, 2024....
Read the full article on Seeking Alpha
For further details see:
Braskem Q4: Challenging But Opportune Scenario For Patient Investors
Braskem SA ADR
NASDAQ: BAK
BAK Trading
-6.19% G/L:
$4.4887 Last:
983,731 Volume:
$4.71 Open:
